Monopar Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$MNPR
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2026
(Exact name of registrant as specified in its charter) |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
(847 ) 388-0349
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
||
The |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 22, 2026, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,698,778 shares of the Company’s common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meeting, of which 5,760,392 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals:
(1) the election of six directors to the Company’s Board of Directors to serve until the Company’s next annual meeting of stockholders or until their respective successors are duly elected and qualified;
(2) the approval of the compensation of the Company’s named executive offers (“NEOs”) on an advisory, non-binding basis;
(3) the approval of the Company’s 2026 Stock Incentive Plan; and
(4) the ratification of the selection of BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
2
Proposal 1 - Election of Directors
At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows:
Director | For | Withheld | Broker Non-Votes |
Christopher M. Starr, Ph.D. | 4,203,485 | 757,652 | 799,255 |
Chandler D. Robinson, MD MBA MSc | 4,447,108 | 514,029 | 799,255 |
Raymond W. Anderson, MBA MS | 4,671,362 | 289,775 | 799,255 |
Kim R. Tsuchimoto | 4,325,379 | 635,758 | 799,255 |
Lavina Talukdar, CFA | 4,897,733 | 63,404 | 799,255 |
Nicole Sweeny | 4,911,758 | 49,379 | 799,255 |
Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.
Proposal 2 - Approval of the Compensation of the Company’s Named Executive Officers on an Advisory, Non-Binding Basis
The voting results with respect to the proposal to approve the compensation of the Company’s NEOs on an advisory, non-binding basis, were as follows:
For | Against | Abstain | Broker Non-Votes |
4,355,628 | 604,858 | 651 | 799,255 |
Accordingly, the Company’s stockholders approved the compensation of the Company’s NEOs on an advisory, non-binding basis.
Proposal 3 – Approval of the Company’s 2026 Stock Incentive Plan
The voting results with respect to the proposal to approve the Company’s 2026 Stock Incentive Plan were as follows:
For | Against | Abstain | Broker Non-Votes |
4,444,209 | 516,570 | 358 | 799,255 |
Accordingly, the Company’s stockholders approved the Company’s 2026 Stock Incentive Plan.
Proposal 4 - Ratification of the Company’s Selection of Independent Registered Public Accounting Firm
The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026, were as follows:
For | Against | Abstain | Broker Non-Votes |
5,759,198 | 998 | 196 | N/A |
Accordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
No other matters were submitted to a vote of stockholders at the Annual Meeting.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Monopar Therapeutics Inc. | |||
Date: June 23, 2026 | By: | /s/ Quan Vu | |
Name: | Quan Vu | ||
Title: | Chief Financial Officer | ||